Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea

References

• Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583–96
   PubMed Web of Science ®Google Scholar
• Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59
   PubMed Web of Science ®Google Scholar
• Gertz MA. How to manage primary amyloidosis. Leukemia 2012;26:191–8
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 2012;30:989–95
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Nuvolone M, Lavatelli F, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007;110:787–8
   PubMed Web of Science ®Google Scholar
• Moreau P, Jaccard A, Benboubker L, Royer B, Leleu X, Bridoux F, Salles G, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010;116:4777–82
   PubMed Web of Science ®Google Scholar
• Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010;28:1031–7
   PubMed Web of Science ®Google Scholar
• Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85–93
   PubMed Web of Science ®Google Scholar
• Goodman HJ, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol 2006;134:417–25
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar S. Transplantation for amyloidosis. Curr Opin Oncol 2007;19:136–41
   PubMed Web of Science ®Google Scholar
• Gertz MA, Lacy MQ, Dispenzieri A, Kumar SK, Buadi FK, Dingli D, Leung N, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant 2011;46:970–5
   PubMed Web of Science ®Google Scholar
• Bellavia D, Pellikka PA, Al-Zahrani GB, Abraham TP, Dispenzieri A, Miyazaki C, Lacy M, et al. Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr 2010;23:643–52
   PubMed Web of Science ®Google Scholar
• Cibeira MT, Sanchorawala V, Seldin DC, Quillen K, Berk JL, Dember LM, Segal A, et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011;118:4346–52
   PubMed Web of Science ®Google Scholar
• Tsai SB, Seldin DC, Quillen K, Berk JL, Ruberg FL, Meier-Ewert H, Sloan JM, et al. High-dose melphalan and stem cell transplantation for patients with AL amyloidosis: trends in treatment-related mortality over the past 17 years at a single referral center. Blood 2012;120:4445–6
   PubMed Web of Science ®Google Scholar
• Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O'Fallon WM, Kurland LT. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817–22
   PubMed Web of Science ®Google Scholar
• Skinner M. AL amyloidosis: the last 30 years. Amyloid 2000;7:13–4
   PubMed Web of Science ®Google Scholar
• Park HJ, Park EH, Jung KW, Kong HJ, Won YJ, Lee JY, Yoon JH, et al. Statistics of hematologic malignancies in Korea: incidence, prevalence and survival rates from 1999 to 2008. Korean J Hematol 2012;47:28–38
   PubMedGoogle Scholar
• Hoshino J, Ubara Y, Sawa N, Sumida K, Hiramatsu R, Hasegawa E, Suwabe T, et al. How to treat patients with systemic amyloid light chain amyloidosis? Comparison of high-dose melphalan, low-dose chemotherapy and no chemotherapy in patients with or without cardiac amyloidosis. Clin Exp Nephrol 2011;15:486–92
   PubMedGoogle Scholar
• Kim SJ, Kim K, Kim BS, Jo DY, Kang HJ, Kim JS, Mun YC, et al. Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. Acta Haematol 2009;122:200–10
   PubMed Web of Science ®Google Scholar
• Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005;79:319–28
   PubMed Web of Science ®Google Scholar
• Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317–25
   PubMed Web of Science ®Google Scholar
• Madan S, Kumar SK, Dispenzieri A, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012;119:1117–22
   PubMed Web of Science ®Google Scholar
• Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995;85:588–96
   PubMed Web of Science ®Google Scholar
• Dreger P, Kloss M, Petersen B, Haferlach T, Loffler H, Loeffler M, Schmitz N. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995;86:3970–8
   PubMed Web of Science ®Google Scholar
• Oran B, Malek K, Sanchorawala V, Wright DG, Quillen K, Finn KT, La Valley M, et al. Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant 2005;35:567–75
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Seldin DC, Skinner M, Quillen K, Doros G, Tan J, O'Hara C, et al. Amyloid deposits in the bone marrow of patients with immunoglobulin light chain amyloidosis do not impact stem cell mobilization or engraftment. Biol Blood Marrow Transplant 2012;18:1935–8
   PubMed Web of Science ®Google Scholar
• Fadia A, Casserly LF, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM. Incidence and outcome of acute renal failure complicating autologous stem cell transplantation for AL amyloidosis. Kidney Int 2003;63:1868–73
   PubMed Web of Science ®Google Scholar
• Taimur S, Nader C, Lloyd-Travaglini C, Seldin DC, Sanchorawala V. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis. Transpl Infect Dis 2013;15:187–94
   PubMedGoogle Scholar
• Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol 2003;122:78–84
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Goodman HJ, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007;109:457–64
   PubMed Web of Science ®Google Scholar
• Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 2004;33:381–8
   PubMed Web of Science ®Google Scholar